RIGL Related Corporate News

May 22, 2013 07:34 AM Rigel Pharma (RIGL) Advances R348 to Phase 2

Apr 5, 2013 06:32 AM AstraZeneca (AZN) Reports Statistically Significant Data from OSKIRA-1

Dec 13, 2012 07:37 AM AstraZeneca (AZN) Updates on OSKIRA-4 Top-Line Results; Did Not Meet Secondary Objective

Oct 3, 2012 09:30 AM Rigel (RIGL) Affirms Pricing 13.7M Offering at $9.50/Share

Oct 3, 2012 08:42 AM Rigel Pharma (RIGL) Said to Price 13.7M Common Offering at $9.50/Share

Jun 19, 2012 08:27 AM AstraZeneca (AZN), Rigel (RIGL) in Exclusive License Agreement for JAK Inhibitor R256

May 26, 2011 09:02 AM Rigel Pharma (RIGL) Prices 16.3M Common Offering at 5.8% Discount

May 6, 2011 07:37 AM Rigel Pharma (RIGL) to Commence Development of R343

Sep 29, 2010 07:49 AM Rigel Pharma (RIGL) Receives $25M From AstraZeneca (AZN) for the Achievement of Two Major Milestones in R788 Development

Sep 22, 2010 05:11 PM AstraZeneca (AZN) Announces Positive Data from Fostamatinib in Patients with RA Who Didn't Respond to MTX

Mar 29, 2010 07:41 AM Rigel Pharma (RIGL) Announces Expiration of HSR Act for License Agreement with AstraZeneca (AZN)

Feb 16, 2010 07:43 AM AstraZeneca (AZN) and Rigel Pharma (RIGL) Announces Fostamatinib Disodium Development Collaboration

Dec 23, 2009 07:41 AM Rigel Pharma (RIGL) Receives Milestone Payment as Part of Cancer Treatment Collaboration

Jul 9, 2009 07:51 AM Rigel's (RIGL) R788 Significantly Improves Rheumatoid Arthritis in Phase 2b Clinical Trial

Dec 8, 2008 09:17 AM Rigel Pharma (RIGL) Reports Results from Phase 2 Trial of R788